首页/数据集/Table S2 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

Table S2 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

Figshare2023-12-15 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Table_S2_from_TEAD_Inhibition_Overcomes_YAP1_TAZ-Driven_Primary_and_Acquired_Resistance_to_KRAS_sup_G12C_sup_Inhibitors/24825235 数据链接链接失效反馈

官方服务：

资源简介：

Compounds/Inhibitors utilized in this study

应用场景：

创建时间：

2023-12-15

肿瘤靶向治疗

药物耐药机制

Protein arginine methyltransferase 5 (PRMT5) over-expression in hematological and solid tumors methylates arginine residues on cellular proteins involved in important cancer functions including cell c

NIAID Data Ecosystem90

Regulation of gene expressions in vivo by anti-VEGF and anti-Notch therapy [HG-U133_Plus_2]

肿瘤靶向治疗

基因表达谱分析

U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine (DBZ), when tumour is established in BALB/c SCID mice. At the e

NIAID Data Ecosystem50

MYC-targeting by OMO-103 in solid tumours: a phase 1 trial

肿瘤靶向治疗

一期临床试验

A Phase I Dose-Escalation Study of a first-in-modality MYC inhibitor, OMO-103, in All-Comers Solid Tumors and identification of potential biomarkers

NIAID Data Ecosystem30

肿瘤靶分子临床研究信息数据集

肿瘤靶向治疗

临床研究

聚焦肿瘤靶分子临床研究全流程，整合靶点发现、临床试验设计、疗效数据、安全性评估等核心信息。数据经标准化清洗与专业校验，关联靶点分子结构、作用机制及临床结果，支持科研机构靶点验证、药企药物研发、临床机构方案优化，为靶分子临床转化提供高质量、可溯源的数据支撑。

江苏数据交易所80

Autonomous rhythmic activity in glioma networks drives brain tumor growth

胶质母细胞瘤机制

肿瘤靶向治疗

Glioblastoma cell networks harbor a plastic population of highly active glioblastoma cells that display rhythmic Ca2+ oscillations and are particularly connected to others. Targeting the autonomous rh

NIAID Data Ecosystem40

Table S2 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

资源简介：

相关数据集